{"groups":[{"description":"Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\\^2). Post-transplant maintenance therapy is then prescribed if appropriate.","id":"FG000","title":"Chemotherapy and Transplant Treatment"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"363"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"363"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}